CareFirst BCBS, ExoDx band together on studies for diagnostic tests
Through CareFirst's new HealthWorx program, the organizations are working together on evidence development studies for ExoDx diagnostic tests.
Q&A: Exosome Diagnostics launches first exosomal RNA-based liquid biopsy test
When it comes to diagnosing cancer, observing RNA has different advantages than just looking at DNA in cancerous cells. Exosome Diagnostics is tapping into the benefits of expanding what's examined to determine a patient's diagnosis as well as optimal treatment plans.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
New non-invasive test for prostate cancer may identify severity of tumor also
Exosome Diagnostic, Inc., has developed a revolutionary non-invasive approach to molecular diagnostic testing that is gaining popularity, especially in the field of prostate cancer detection and prognosis. The company, based in New York, was founded in 2008 and has licensed its proprietary exosome technology from Massachusetts General Hospital for use in the development of […]